文献速递前列腺癌

美国转移性前列腺癌患者镭-223真实世界使用模式与生存分析

Real-world utilization patterns and survival in men with metastatic prostate cancer treated with Radium-223 in the United States.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-04-04

该回顾性队列利用2017至2022年私人保险数据,分析1376例接受镭-223(Ra-223)治疗的转移性去势抵抗性前列腺癌(mCRPC)患者的用药模式与真实世界总生存(rwOS)。中位rwOS为22.9个月;完成至少5个周期及联合/分层治疗者生存更长,校正后死亡风险分别降低55%和22%。

要点

  • 完成至少5个周期Ra-223者中位rwOS为30.3个月,优于1至4个周期的15.3个月
  • 联合/分层治疗者中位rwOS为26.6个月,优于单药治疗的20.5个月
  • 校正分析中联合/分层治疗与完成至少5个周期分别与死亡风险降低22%和55%相关

核心结论

  • 接受Ra-223治疗的患者中,较早治疗线数、联合其他治疗及完成至少5个周期与真实世界总生存获益相关,提示Ra-223在当前治疗格局中仍具重要性。

研究设计与样本

  • 回顾性队列研究,数据来自Komodo Health私人保险数据库,纳入2017年1月1日至2022年6月30日接受Ra-223治疗的mCRPC男性1376例。
  • 采用Cox回归分析Ra-223使用与rwOS的关联,并校正协变量。

主要发现

  • 1376例患者中位年龄68岁,51%为白人,89%为仅骨转移。
  • 17%、35%、25%的患者分别将Ra-223作为mCRPC一线、二线、三线治疗。
  • 总体中位rwOS为22.9个月。
  • 完成至少5个周期者中位rwOS为30.3个月,1至4个周期者为15.3个月;联合/分层治疗为26.6个月,单药为20.5个月。

关键数值与推荐

  • 校正分析中,联合/分层治疗与死亡风险降低22%相关,完成至少5个Ra-223周期与死亡风险降低55%相关。

临床怎么用

  • 对适合的mCRPC患者可考虑较早使用Ra-223、联合其他治疗并尽量完成至少5个周期,以争取更好真实世界生存。

局限性

  • 理赔数据库未能捕获部分临床信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) has evolved since radium-223 (Ra-223) was approved in the United States (2013). We examined treatment patterns and real-world overall survival (rwOS) of men with mCRPC treated with Ra-223 in the modern treatment era. METHODS: A retrospective cohort of men treated with Ra-223 was derived using private insurance data from the Komodo Health dataset from January 1, 2017 to June 30, 2022. Cox-regression analyses examined associations between Ra-223 use and rwOS with adjustment for covariates. RESULTS: Of 1376 men, the median age was 68 years, 51% were White, and 89% had bone-only metastases. Overall, 17%, 35%, and 25% of men received Ra-223 as first-line, second-line, or third-line treatment for mCRPC, respectively. Thirty-six percent received Ra-223 as combination/layered therapy, mainly with enzalutamide, and 46% completed ≥5 cycles. Overall, median rwOS was 22.9 months. Median rwOS was longer in men who completed ≥5 Ra-223 cycles versus 1-4 cycles (30.3 versus 15.3 months) and combination/layered therapy versus monotherapy (26.6 versus 20.5 months). Combination/layered therapy and completion of ≥5 Ra-223 cycles were associated with 22% and 55% reductions in risk of death in adjusted analyses, respectively. Limitations include some clinical information not captured by claims databases. CONCLUSIONS: Significant rwOS benefits were identified in men who received Ra-223 as an earlier line of therapy, received Ra-223 in combination with another therapy, and completed ≥5 Ra-223 cycles, underscoring the importance of Ra-223 in the current treatment landscape.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Raval AD, Zhang Y, Korn M, et al. Real-world utilization patterns and survival in men with metastatic prostate cancer treated with Radium-223 in the United States. Prostate Cancer Prostatic Dis. 2025. PMID: 40185917. doi:10.1038/s41391-025-00969-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。